Breaking News Instant updates and real-time market news.

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

, VNRX

VolitionRx

$2.95

0.0441 (1.52%)

14:31
01/17/18
01/17
14:31
01/17/18
14:31

Analysts stay bullish on Exact Sciences after ASCO abstract prompts pullback

Shares of Exact Sciences (EXAS), the maker of the Cologuard test for the early detection and prevention of some forms of cancer, are dropping after the release on the site of the American Society of Clinical Oncology of an abstract regarding a new study assessing a liquid biopsy test for colorectal cancer, CRC, that showed up to 88% accuracy. Several Wall Street analysts have since commented on the news saying the selloff in the shares is overdone. Canaccord's Mark Massaro told investors that he sees this as a "golden buying opportunity." COMPETITOR DATA: According to an abstract entitled "Liquid Biopsy Test Shows Promise for Detecting Early-Stage Colorectal Cancer" that was released on the site of the American Society of Clinical Oncology, a new study has found that a test that identifies circulating tumor cells present in the bloodstream can detect colorectal cancer at an early stage, with accuracy ranging from 84 to 88%. The blood samples were processed using CMx, an assay that captures rare CTCs - such as those found in early-stage cancer - on a lipid-coated chip that mimics human tissue, the abstract read. SELLOFF OVERDONE: Following news of the ASCO abstract, Baird analyst Catherine Ramsey argued that the selloff in Exact Sciences' shares is overdone based on some seemingly large issues with this study's design. While several companies are working on blood-based CRC screening tests such as VolitionRx (VNRX), which is planning near-term interim data releases, Ramsey still believes a potential U.S. blood test is many years away. Her peer at Cowen voiced a similar opinion, saying he also sees the selloff in Exact shares as overdone. While analyst Doug Schenkel acknowledged that the data looks "interesting," he noted that it is a relatively small, single-site study that includes a disproportionate number of diseased patients. Additionally, the analyst pointed out that there are also questions about study design, which looks to be biased by disease state and it is unclear if FDA-level standards were applied. Schenkel reiterated an Outperform rating and $65 price target on Exact Sciences' shares. Meanwhile, William Blair analyst Brian Weinstein also told investors that he believes the blood-based CRC screening test highlighted by ASCO has large issues with its study design. Of the 620 subjects in the study, 18% had pre-cancer and another 53% had cancer, which likely skews the specificity much higher than if the study were done on the typical U.S. population, Weinstein contended. The analyst reiterated an Outperform rating on Exact Sciences' stock. 'GOLDEN' BUYING OPPORTUNITY: In a research note of his own, Canaccord's Massaro told investors that the selloff today in shares of Exact Sciences presents a "golden buying opportunity," particularly for investors who have been on the sidelines. The analyst believes there are "fundamental issues" to this study and reasons to be skeptical of it. Further, Massaro argued that this study is "apples-and-oranges" different than Exact Sciences' Deep-C Study, which got Cologuard approved by the FDA and into guidelines. The latter had about 10,000 patients who were asymptomatic, while the former enrolled 182 healthy and 438 who were symptomatic, he pointed out, adding that to conclude that this study is a meaningful competitor to Cologuard does not make sense to him. The analyst reiterated a Buy rating and $60 price target on the shares, and said Exact Sciences remains a top pick for 2018. PRICE ACTION: In afternoon trading, shares of Exact Sciences have dropped over 8% to $48.50.

EXAS

Exact Sciences

$52.95

0.33 (0.63%)

VNRX

VolitionRx

$2.95

0.0441 (1.52%)

  • 19

    Jan

  • 26

    Feb

EXAS Exact Sciences
$52.95

0.33 (0.63%)

01/17/18
ADAM
01/17/18
NO CHANGE
ADAM
Buy
Canaccord sees 'golden buying opportunity' amid Exact Sciences selloff
The selloff today in shares of Exact Sciences presents a "golden buying opportunity," particularly for investors who have been on the sidelines, Canaccord Genuity analyst Mark Massaro tells investors in a research note. The stock in midday trading is down 8%, or $4.12, to $48.82. The analyst sees "fundamental issues" with the study highlighted in abstracts ahead of the upcoming 2018 Gastrointestinal Cancers Symposium. The 620 patient study is "apples-and-oranges different" than Exact Sciences' Deep-C Study, which got Cologuard approved by the FDA and into guidelines, Massaro argues. He points out that Exact's study had around 10,000 patients who were asymptomatic, while the Taiwanese liquid biopsy study enrolled 182 healthy and 438 who were symptomatic. The analyst recommends buying Exact Sciences "aggressively" on today's selloff. Massaro has a Buy rating on the name with a $60 price target.
01/17/18
WBLR
01/17/18
NO CHANGE
WBLR
ASCO abstract 'far from comparable' to Exact's Cologuard, says William Blair
William Blair analyst Brian Weinstein views the pullback today in shares of Exact Sciences as overdone. In a research note titled "ASCO Abstract Far from Comparable to Cologuard," the analyst says the blood-based colorectal cancer screening test highlighted today by ASCO has large issues with its study design. Of the 620 subjects in the study, 18% had pre-cancer and another 53% had cancer, which likely skews the specificity much higher than if the study were done on the typical U.S. population, Weinstein writes. He has an Outperform rating on Exact Sciences.
01/17/18
COWN
01/17/18
NO CHANGE
Target $65
COWN
Outperform
Exact Sciences selloff today is overdone, says Cowen
Cowen analyst Doug Schenkel views today's selloff in shares of Exact Sciences as overdone. The analyst thinks the data of a blood-based colorectal cancer screening test look "interesting," but notes the study highlighted in an ASCO abstract is "relatively small" with a disproportionate amount of diseased patients. He has questions over the study design and keeps an Outperform rating on Exact Sciences with a $65 price target.
01/17/18
LEER
01/17/18
NO CHANGE
LEER
Exact Sciences shares defended at Leerink
VNRX VolitionRx
$2.95

0.0441 (1.52%)

01/17/18
BARD
01/17/18
NO CHANGE
BARD
Exact Sciences selloff overdone after ASCO abstract, says Baird
Baird analyst Catherine Ramsey attributes the sharp selloff in Exact Sciences (EXAS) shares to news of an ASCO abstract on a liquid biopsy test for colorectal cancer screening. However, based on some seemingly large issues with this study's design, she argues that the selloff is overdone. Several companies are working on blood-based CRC screening tests, with VolitionRx (VNRX) at least one that is planning near-term interim data releases, but Ramsey still believes a potential U.S. blood test is many years away, she tells investors.

TODAY'S FREE FLY STORIES

CCB

Coastal Financial

$0.00

(0.00%)

21:11
07/17/18
07/17
21:11
07/17/18
21:11
Syndicate
Coastal Financial 2.85M share IPO priced at $14.50 »

The deal range was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

CRNX

Crinetics

$0.00

(0.00%)

21:08
07/17/18
07/17
21:08
07/17/18
21:08
Syndicate
Crinetics 6M share IPO priced at $17.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 18

    Jul

NSTG

NanoString

$12.74

-2.36 (-15.63%)

21:07
07/17/18
07/17
21:07
07/17/18
21:07
Syndicate
NanoString 4M share Secondary priced at $12.50 »

JPMorgan and UBS acted as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 08

    Aug

  • 18

    Jul

ALV

Autoliv

$106.86

1.57 (1.49%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Autoliv rating change  »

Autoliv downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VC

Visteon

$131.71

3.58 (2.79%)

21:06
07/17/18
07/17
21:06
07/17/18
21:06
Downgrade
Visteon rating change  »

Visteon downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 07

    Aug

ABT

Abbott

$62.84

1.05 (1.70%)

, MS

Morgan Stanley

$49.20

0.29 (0.59%)

20:25
07/17/18
07/17
20:25
07/17/18
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

ABT

Abbott

$62.84

1.05 (1.70%)

MS

Morgan Stanley

$49.20

0.29 (0.59%)

USB

U.S. Bancorp

$51.29

-0.01 (-0.02%)

TXT

Textron

$66.81

0.14 (0.21%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

  • 18

    Jul

ADTN

Adtran

$16.05

0.1 (0.63%)

20:14
07/17/18
07/17
20:14
07/17/18
20:14
Earnings
Adtran reports Q2 adjusted EPS (10c), two estimates (32c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

, ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

20:09
07/17/18
07/17
20:09
07/17/18
20:09
Hot Stocks
FS Bancorp to merge with Anchor Bancorp in $77M deal »

FS Bancorp (FSBW) and…

FSBW

FS Bancorp

$61.64

-1.86 (-2.93%)

ANCB

Anchor Bancorp

$28.50

0.3 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$26.41

-1.19 (-4.31%)

20:06
07/17/18
07/17
20:06
07/17/18
20:06
Hot Stocks
Breaking Hot Stocks news story on Canopy Growth  »

Greenstar Canada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$356.95

0.94 (0.26%)

19:10
07/17/18
07/17
19:10
07/17/18
19:10
Hot Stocks
Boeing awarded $3.9B government contract »

Boeing has been awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

MRTN

Marten Transport

$22.10

(0.00%)

, UAL

United Continental

$72.66

0.38 (0.53%)

19:03
07/17/18
07/17
19:03
07/17/18
19:03
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS: Martin…

MRTN

Marten Transport

$22.10

(0.00%)

UAL

United Continental

$72.66

0.38 (0.53%)

CSX

CSX

$64.42

0.46 (0.72%)

MLNX

Mellanox

$84.85

0.9 (1.07%)

IBKR

Interactive Brokers

$64.65

1.93 (3.08%)

HCSG

Healthcare Services

$42.38

-0.3297 (-0.77%)

TXN

Texas Instruments

$115.80

1.21 (1.06%)

SAH

Sonic Automotive

$20.45

0.3 (1.49%)

CARA

Cara Therapeutics

$21.60

0.435 (2.06%)

CASI

Casi Pharmaceuticals

$7.26

-0.215 (-2.88%)

TLYS

Tilly's

$15.35

0.21 (1.39%)

CLX

Clorox

$135.00

0.71 (0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 17

    Jul

  • 18

    Jul

  • 18

    Jul

  • 24

    Jul

  • 02

    Aug

  • 26

    Aug

  • 19

    Jul

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:38
07/17/18
07/17
18:38
07/17/18
18:38
Hot Stocks
BHP Billiton sees FY19 copper equivalent output broadly in line with FY18 »

Says expects to achieve…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BHP

BHP Billiton

$48.73

0.24 (0.49%)

18:35
07/17/18
07/17
18:35
07/17/18
18:35
Hot Stocks
BHP Billiton reports Q4 petroleum production 49 MMBOE, down 6% »

Reports Q4 copper…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLX

Clorox

$135.00

0.71 (0.53%)

18:31
07/17/18
07/17
18:31
07/17/18
18:31
Downgrade
Clorox rating change at Goldman Sachs »

Clorox downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

NCS

NCI Building

$20.70

0.15 (0.73%)

18:27
07/17/18
07/17
18:27
07/17/18
18:27
Hot Stocks
NCI Building Systems, Ply Gem Parent to combine in stock-for-stock merger »

NCI Building Systems and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

, AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

18:16
07/17/18
07/17
18:16
07/17/18
18:16
Earnings
America Movil reports Q2 operating profit MXN32.6M, up 4.8% from last year »

Reports Q2 revenue…

AMX

America Movil, also tag AMOV

$17.39

-0.35 (-1.97%)

AMOV

America Movil, also tag AMX

$17.45

-0.19 (-1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,844.00

21.98 (1.21%)

18:08
07/17/18
07/17
18:08
07/17/18
18:08
Recommendations
Amazon.com analyst commentary at Piper Jaffray »

Amazon.com price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 26

    Jul

  • 16

    Aug

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

, BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

18:06
07/17/18
07/17
18:06
07/17/18
18:06
Hot Stocks
Berkshire Hathaway amends share repurchase program »

The Board of Directors of…

BRK.A

Berkshire Hathaway

$288,482.00

-1118 (-0.39%)

BRK.B

Berkshire Hathaway

$190.47

-1.52 (-0.79%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PNFP

Pinnacle Financial

$60.10

-0.5 (-0.83%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Earnings
Pinnacle Financial reports Q2 EPS $1.15, consensus $1.14 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jul

  • 24

    Sep

CHDN

Churchill Downs

$304.60

1.1 (0.36%)

18:02
07/17/18
07/17
18:02
07/17/18
18:02
Hot Stocks
Churchill Downs receives approval to increase historical racing machines »

Churchill Downs announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Aug

CE

Celanese

$110.22

1.6 (1.47%)

18:01
07/17/18
07/17
18:01
07/17/18
18:01
Hot Stocks
Celanese announces acetic acid price increases in Asia »

Celanese Corporation will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Jul

BLK

BlackRock

$504.89

1.14 (0.23%)

17:51
07/17/18
07/17
17:51
07/17/18
17:51
Hot Stocks
BlackRock raises quarterly dividend to $3.13 from $2.88 per share »

The dividend is payable…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DRNA

Dicerna

$12.47

0.57 (4.79%)

17:45
07/17/18
07/17
17:45
07/17/18
17:45
Conference/Events
Dicerna management to meet with SunTrust »

Group dinner to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

, GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

17:44
07/17/18
07/17
17:44
07/17/18
17:44
Periodicals
Google faces record EU fine over Android dominance, FT reports »

Alphabet's Google…

GOOG

Alphabet

$1,198.81

14.57 (1.23%)

GOOGL

Alphabet Class A

$1,213.65

17.07 (1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jul

  • 17

    Jul

  • 23

    Jul

  • 23

    Jul

  • 08

    Aug

  • 18

    Sep

  • 28

    Oct

BA

Boeing

$356.95

0.94 (0.26%)

17:39
07/17/18
07/17
17:39
07/17/18
17:39
Periodicals
Breaking Periodicals news story on Boeing »

Boeing awarded $3.9B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.